Mouse bone marrow-derived Lin − -Sca-1 + endothelial progenitor cell (EPC) has pluripotent abilities such as supporting neovascularization. Vascular endothelial growth factor (VEGF) receptor 1 (VEGFR1) (Flt1) recognizes various VEGF isoforms and is critically implicated in a wide range of physiological and pathological settings, including vasculogenesis. Mouse EPC expresses two isoforms of VEGFR1: mFlt1, which transmits ligand-induced signals; and sFlt1, which acts as a negative regulator by sequestering ligands of VEGF receptors. How the relative levels of mFlt1 and sFlt1 are regulated is not yet clear. We report here that tumor necrosis factor superfamily 15 (TNFSF15) (also known as VEGI or TL1A), an endothelial cell-secreted cytokine, simultaneously promotes mFlt1 degradation and up-regulates sFlt1 expression in EPC, giving rise to disruption of VEGF-or PlGF-induced activation of eNOS and MAPK p38 and effective inhibition of VEGF-driven, EPC-supported vasculogenesis in a murine Matrigel implant model. TNFSF15 treatment of EPC cultures facilitates Akt deactivationdependent, ubiquitin-assisted degradation of mFlt1 and stimulates sFlt1 expression by activating the PKC, Src, and Erk1/2 signaling pathway. Additionally, TNFSF15 promotes alternative splicing of the Flt1 gene in favor of sFlt1 production by down-regulating nuclear protein Jumonji domain-containing protein 6 (Jmjd6), thus alleviating Jmjd6-inhibited sFlt1 expression. These findings indicate that TNFSF15 is a key component of a molecular mechanism that negatively modulates EPC-supported vasculogenesis through regulation of the relative levels of mFlt1 and sFlt1 in EPC. 
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Vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) promote vasculogenesis (14, (16) (17) (18) . VEGF receptor 1 [VEGFR1 or fms-related tyrosine kinase 1 (Flt1)] is a receptor tyrosine kinase that mediates VEGF-A, VEGF-B, and PlGF-induced signals in a wide range of physiological and pathological settings of hematopoiesis and neovascularization (19) (20) (21) . BMderived VEGFR1
+ stem/progenitor cells promote tumor angiogenesis (22) , initiate tumor premetastatic niche (23) , and take part in reconstitution of hematopoiesis (1) . The VEGFR1 gene has two products, membrane-bound mFlt1 and soluble sFlt1 (24) . Membrane-bound mFlt1 is the full-length, fully functional VEGFR1. Soluble sFlt1 consists of only the extracellular domain of VEGFR1 and is incapable of transmitting signal across cell membrane. However, because of its high-affinity ligand binding ability, sFlt1 acts as a negative modulator by trapping VEGF-A, VEGF-B, and PlGF, preventing neovascularization promoted by these cytokines (25) (26) (27) . It has been shown that sFlt1 inhibits tumor angiogenesis (28) and metastasis (29) , binds lipid microdomains in kidney podocytes to control cell morphology and glomerular barrier function (30) , regulates tip cell formation and branching morphogenesis in the zebra fish embryo (31) , and plays a causal role in the pathogenesis of preeclampsia (32) . In clinical settings, sFlt1 levels are of prognostic value in acute myocardial infarction (33) .
The relative levels of mFlt1 and sFlt1 are closely regulated under specific physiological or pathological conditions. When ECs are exposed to VEGF, PI3K-Akt signals are activated to inhibit ubiquitin-assisted degradation of mFlt1 such that mFlt1 levels rapidly increase (34) . Alternative splicing of the Flt1 gene is attributable to sFlt1 production (25, 35) . The alternative splicing is regulated by Jumonji domain-containing protein 6 (Jmjd6) a nuclear protein that inhibits sFlt1 splicing (36) . Despite the importance of the relative levels of proangiogenic mFlt1 and antiangiogenic sFlt1 in neovascularization, the molecular mechanism regulating concomitant changes of these two isoforms remains unclear.
Tumor necrosis factor superfamily 15 (TNFSF15) (also known as VEGI or TL1A), a cytokine produced predominantly by EC in established blood vessels, is a specific inhibitor of EC proliferation (37), being able to enforce growth arrest on quiescent EC but induce apoptosis in proliferating EC (38) . Systemic administration of recombinant TNFSF15 led to inhibition of tumor angiogenesis and growth in animal models (39) . It also inhibits Lin − -Sca-1 + EPC differentiation into EC (6) and EPC incorporation into tumor vasculature in murine models (10) . TNFSF15 expression is absent or marginal in tumor vasculatures in various cancers (40) (41) (42) , increased in irritable bowel syndrome (43) , and down-regulated in wound tissues (44) . TNFSF15 down-regulation in ovarian cancer is facilitated by VEGF secreted by cancer cells as well as by other inflammatory cytokines (42) . Death domaincontaining receptor 3 (DR3) (TNFRSF25), a member of the TNF receptor superfamily, has been shown to be the receptor of TNFSF15 in T cells and dendritic cells (45, 46) .
We report here that TNFSF15 inhibits EPC-supported vasculogenesis by promoting ubiquitin-assisted degradation of mFlt1 while facilitating Flt1 gene transcription and alternative splicing toward increased sFlt1 production. These findings provide insights into a molecular mechanism that interlocks the actions of TNFSF15 and VEGFR1 signals. (Fig. 1A) . Blood vessel densities on cross-sections of the vehicle-treated plugs were more than four times of that of TNFSF15-treated plugs (Fig. 1B) . Superimposition of fluorescent confocal microscopic images of the cross-sections revealed that the new blood vessels (EC marker CD31 (Fig. 1C) . A small number of the new blood vessels did not contain EPC-derived EC, and thus remained red-colored in the merged images. These data demonstrate that BM-derived EPCs are capable of supporting vasculogenesis and that TNFSF15 is able to inhibit EPC-supported vasculogenesis in this model.
Results

TNFSF15
TNFSF15 Inhibits Vasculogenesis Through Down-Regulation of mFlt1
and Up-Regulation of sFlt1. To determine the effect of TNFSF15 on mFlt1 and sFlt1 levels in VEGF-driven, EPC-supported vasculogenesis, we carried out immunofluorescent staining of the mFlt1 protein on frozen sections of the Matrigel plugs. We found that the mFlt1 protein diminished markedly as a result of TNFSF15 treatment ( Fig. 2A) . Fluorescence intensity assessment revealed that mFlt1 protein levels in vehicle-treated plugs were four times of that in TNFSF15-treated ones (Fig. 2B) . We then digested the gel plugs, isolated the cells, labeled mFlt1 with allophycocyanin, and carried out flow-cytometric analysis (Fig. 2C) . The percentage of mFlt1-positive cells in vehicle-treated plugs was three times that in TNFSF15-treated ones (Fig. 2D) . We determined sFlt1 concentrations in cell-free supernatants of the digested plugs by ELISA and found that sFlt1 levels in TNFSF15-treated plugs were about three times that in vehicle-treated ones (Fig. 2E) . Western blotting analysis of the plugs indicated that mFlt1 levels decreased by fivefold, whereas sFlt1 protein levels increased by sixfold (Fig. 2 F and G) . These findings indicate that simultaneous down-regulation of mFlt1 and up-regulation of sFlt1 may attribute to TNFSF15 inhibition of vasculogenesis.
To determine whether down-regulation of mFlt1 or up-regulation of sFlt1 in EPC would lead to inhibition of vasculogenesis, we supplemented the EPC-and VEGF-containing Matrigel solution with mFlt1 siRNA (25 μg/mL) or recombinant sFlt1 (sFlt1-Fc, 25 μg/mL), or both. The gel plugs were retrieved on day 7. The mFlt1 siRNA treatment caused a substantial decline of mFlt1 ( (Fig. 3A) . The treatment led to a 66% down-modulation of mFlt1 (Fig. 3B) . Presence of a TNFSF15 neutralizing antibody, 4-3H (0.4 mg/mL), in the culture media prevented the down-modulation (Fig. 3B) . The blockage of TNFSF15-induced mFlt1 down-modulation by 4-3H was dose dependent (Fig. 3C) . Using an antibody that recognizes both mFlt1 and sFlt1, we found by Western blotting analysis that the mFlt1 protein diminished within 30 min following TNFSF15 treatment and remained suppressed for at least 24 h, whereas cellassociated sFlt1 protein level increased significantly within 12 h and remained high at 24 h (Fig. 3D) . We determined sFlt1 concentrations in EPC culture media by ELISA and found that within 24 h sFlt1 levels in TNFSF15-treated cultures increased by about twofold, whereas 4-3H effectively stopped the increase (Fig. 3E) . By using RT-PCR, we found that TNFSF15 treatment gave rise to 7-and 15-fold increase of mFlt1 and sFlt1 mRNA levels, respectively, within 24 h (Fig. 3F ). These findings indicate that TNFSF15 facilitates mFlt1 protein degradation, enhances sFlt1 secretion, and stimulates mFlt1 and sFlt1 mRNA production in EPC.
TNFSF15 Treatment Alters Signaling Pathways Regulating mFlt1
Degradation. The rapid mFlt1 degradation suggests an involvement of the ubiquitin-proteasome pathway. We thus treated EPC with ubiquitin inhibitor PYR-41 at various concentrations for 2 h before TNFSF15 treatment (0.3 μg/mL, 30 min). PYR-41 at 20 μM effectively prevented TNFSF15-stimulated mFlt1 degradation (Fig.  4A) . We also treated EPC with proteasome inhibitor MG132 at various concentrations (2 h) before TNFSF15 treatment and found that MG132 also inhibited TNFSF15-induced mFlt1 degradation (Fig. 4B) . To determine whether TNFSF15-induced mFlt1 degradation was reversible, we treated EPC with TNFSF15 for 30 min, and then replaced the culture media without TNFSF15. We found that mFlt1 protein level gradually restored upon TNFSF15 removal (Fig. 4C) . Additionally, we found that TNFSF15-induced mFlt1 degradation was accompanied by Akt deactivation and that concomitant Akt reactivation and mFlt1 restoration occurred once TNFSF15 was removed (Fig. 4C) . These data suggest that TNFSF15 treatment results in Akt deactivation, which is required for ubiquitin-assisted mFlt1 degradation. Because Akt is a substrate of phosphoinositol-3-kinase (PI3K), we pretreated EPC with PI3K inhibitor LY294002 (50 μM, 2 h) or DMSO, followed by treatment with TNFSF15. We found that LY294002 treatment effectively led to mFlt1 degradation and that TNFSF15 was no longer able to induce mFlt1 degradation in the presence of LY294002 (Fig. 4D) . These findings are consistent with the view that TNFSF15-induced mFlt1 degradation in EPC is mediated through the ubiquitin-proteasome route, which is Akt deactivation dependent.
Intracellular Signaling Pathways Involved in TNFSF15-Stimulated sFlt1
Production in EPC. EC secretion of sFlt1 is promoted by the activation of PKC, Src, and Erk1/2 signals (47). To find out whether this signaling pathway is involved in TNFSF15-stimulated sFlt1 secretion by EPC, we treated the cells with PKC activator phorbol myristate acetate (PMA) (100 ng/mL, 2 h) or PKC inhibitor GF109203X (5 μM, 2 h), and then added TNFSF15 (0.3 μg/mL) to the media, and evaluated sFlt1 mRNA levels in 24 h by RT-PCR. PMA treatment led to an increase of sFlt1 mRNA with or without TNFSF15, whereas GF109203X suppressed TNFSF15-induced sFlt1 up-regulation (Fig. 5A) . Antibody 4-3H inhibited TNFSF15-induced, but not PMA-induced, sFlt1 mRNA production. These findings suggest that TNFSF15 stimulation of sFlt1 production in EPC is mediated through the activation of PKC.
We then treated EPC with Src inhibitor PP2 (10 μM), Erk1/2 inhibitor U0126 (10 μM), or Akt inhibitor LY294002 (50 μM) for 2 h, and then with TNFSF15 or vehicle in the presence of each of the inhibitor for 24 h. RT-PCR analysis showed that PP2 and U0126 suppressed TNFSF15-induced sFlt1 up-regulation, whereas LY294002 had no effect (Fig. 5B) . In addition, we treated the cells with 4-3H, GF109203X, or U0126 for 2 h, and then added TNFSF15, and analyzed in 6 h for phospho-Src by using flow cytometry (Fig. 5C) . The percentage of phospho-Src-positive cells increased by 1.6-fold in response to TNFSF15, and the change was blocked by 4-3H or GF109203X, but not by U0126 (Fig. 5D) . Moreover, we treated the cells with 4-3H, GF109203X, or PP2 for 2 h, and then added TNFSF15, and analyzed in 6 h for phosphoErk1/2 by flow cytometry (Fig. 5E) . The percentage of phosphoErk1/2-positive cells increased by twofold upon TNFSF15 treatment; this enhancement diminished, however, when the cells were pretreated with 4-3H, GF109203X, or PP2 (Fig. 5F ). These data indicate that TNFSF15-stimulated sFlt1 expression in EPC is mediated through the activation of PKC, Src, and Erk1/2. Because the The experiments were repeated two times. Data are mean ± SD. *P < 0.05, **P < 0.01, Student t test.
Erk inhibitor U0126 had no effect on TNFSF15-induced Srcphosphorylation, whereas the Src inhibitor PP2 effectively suppressed TNFSF15-induced Erk1/2-phosphorylation, the TNFSF15-activated signals proceeds along the PKC-Src-Erk1/2 axis. Furthermore, we analyzed the effect of TNFSF15 action on Flt1 gene transcript alternative splicing. Because nuclear protein Jmjd6 inhibits sFlt1 mRNA production, we treated EPC with TNFSF15 for 6 h and analyzed Jmjd6 levels by immunofluorescent staining. TNFSF15 treatment resulted in marked decline of Jmjd6, which was restored by 4-3H (Fig. 5G) . Quantitative analysis revealed an about 80% decrease of Jmjd6 fluorescence intensity (Fig. 5H) . The inhibition of Jmjd6 activity by TNFSF15 was dose dependent, with an IC 50 value of about 80 ng/mL (Fig. 5I) . These findings indicate that TNFSF15 inhibits Jmjd6 activity, and this leads to a relief of Jmjd6-suppressed Flt1 transcript splicing, giving rise to increased sFlt1 production.
TNFSF15 Suppresses EPC Response to VEGF or PlGF Stimulation. It is known that mFlt1 mediates VEGF-induced endothelial nitric oxide synthase (eNOS) and MAPK p38 phosphorylation in EC (19, 48) , and that mFlt1 mediates PlGF-induced p38 activation (49) . We treated the cells with TNFSF15 (0.3 μg/mL, 30 min), replaced the media without TNFSF15, and treated the cells with or without VEGF (10 ng/mL, 2 min) or PlGF (10 ng/mL, 5 min). We found that VEGF was no longer able to induce eNOS or p38 phosphorylation in TNFSF15-treated EPC until mFlt1 is restored upon TNFSF15 removal (Fig. 6A) . Similarly, PlGF-induced activation of p38 was prevented by TNFSF15 treatment (Fig. 6B) . As VEGFR2 may also transmit VEGF or PlGF activities, we determined VEGFR2 expression in freshly isolated EPC and found that the cells did not express VEGFR2 up to 6 d in culture (Fig.  6C) . Thus, VEGFR2 is unlikely to account for the transmission of VEGF or PlGF signals in freshly isolated EPC. To determine the VEGF-sequestering ability of sFlt1 in TNFSF15-treated EPC, we analyzed VEGF interaction with sFlt1 in EPC culture media after 24 h treatment of the cells with TNFSF15. By carrying out Western blotting under nondenaturing conditions, we found a shift of VEGF from a free form (molecular mass, 50 kDa) to sFlt1-bound form (molecular mass, 110 kDa) (Fig. 6D) . These findings indicate that TNFSF15-facilitated mFlt1 down-regulation and sFlt1 upregulation leads to inhibition of EPC responsiveness to VEGF or PlGF. 
Discussion
Our data demonstrate that TNFSF15 simultaneously down-regulates mFlt1 and up-regulates sFlt1 levels in EPC. The regulation plausibly involves three pathways (Fig. 7) . First, TNFSF15 promotes Akt deactivation-dependent, ubiquitin-mediated mFlt1 protein degradation. Second, TNFSF15 stimulates mFlt1 and sFlt1 mRNA transcription by activating the PKC-Src-Erk1/2 signaling axis. Third, TNFSF15 induces Jmjd6 down-regulation and thus alleviates Jmjd6 inhibition of Flt1 transcript differential splicing toward sFlt1, enhancing sFlt1 production. These findings are highly significant in twofold. First, they show that the activity of the VEGF-VEGFR1 signaling pathway on EPC-supported vasculogenesis can be directly regulated by TNFSF15, a negative modulator of angiogenesis produced largely by EC in a normal vasculature. Second, the findings reveal a mechanism in which the production of the two VEGFR1 isoforms in EPC can be regulated simultaneously by TNFSF15, with an outcome in favor of an inhibition of EPC-supported vasculogenesis.
We showed previously that TNFSF15 gene expression in EC is down-regulated by VEGF produced by ovarian cancer cells (42) . This indicates that the actions of a positive modulator of angiogenesis, namely VEGF, may lead to the removal from tumor microenvironment of a negative modulator of angiogenesis, namely TNFSF15, which would otherwise functions as an obstacle in the initiation or continuation of tumor angiogenesis. Our findings that TNFSF15 inhibits VEGF-induced vasculogenesis by simultaneously down-regulating mFlt1 and up-regulating sFlt1 point to the presence of a mechanism in which the actions of TNFSF15 and VEGF are interlocked. It is plausible that this mechanism is a critical component of the "angiogenesis switch" proposed by Folkman and Hanahan two decades ago (50) . Further investigation of the interlocked actions of TNFSF15 and VEGF may help to materialize the angiogenesis switch at molecular level.
The paracrine and autocrine aspects of the actions of TNFSF15, VEGF, sFlt1, and mFlt1 on EPC are important because the initiation of new blood vessel formation is the result of joint actions of mFlt1-or sFlt1-expressing EPC, TNFSF15-producing EC, VEGFor PlGF-producing cells such as inflammatory immune cells, other stromal cells, or cancer cells, at the site of vascular repair or in the tumor microenvironment. Under physiological conditions, TNFSF15 is mainly secreted by EC in established blood vessels. The action of EC-secreted TNFSF15 on EPC facilitates sFlt1 autocrine and down-regulates mFlt1 at the same time, diminishing EPC responsiveness to VEGF, a major stimulus of EPC proliferation and differentiation. Under pathological conditions such as in ischemic tissues or cancer lesions, however, TNFSF15 expression in EC is down-regulated by VEGF prominently secreted by hypoxic EC or cancer cells. Down-modulation of TNFSF15 will not only relieve an inhibition on EPC differentiation into EC, but also lead to reduced sFlt1 production by EPC, thus enhancing EPC responsiveness to VEGF, facilitating EPC participation in neovascularization. A cell surface receptor mediating TNFSF15 action on EPC is yet to be identified, because the currently known TNFSF15 receptor DR3 is not expressed in freshly isolated EPC, as we reported previously (6) and confirmed in this study (Fig. S2) .
It is interesting to notice that TNFSF15 treatment leads to a rapid degradation of the mFlt1 protein and at the same time a significant increase of both mFlt1 and sFlt1 mRNA. The latter is likely due to a common transcription initiation site in the Flt1 gene for the transcription of both mFlt1 and sFlt1 (51), causing concomitant expression of sFlt1 and mFlt1. TNFSF15 inhibition on Jmjd6 activity encourages a shift of Flt1 alternative splicing toward sFlt1 mRNA production.
In summary, this study reveals a mechanism underlying the modulation of vasculogenesis supported by EPC. Our finding that TNFSF15 treatment of EPC results in a shift of mFlt1 and sFlt1 balance in favor of sFlt1 secretion is significant because the relative levels of the two isoforms of VEGFR1 are a critical attribute in determining the activities of growth factors such as VEGF and PlGF in organ generation, tissue repair, as well as in tumor neovascularization.
Materials and Methods
Cells. Mouse BM-derived Lin − -Sca-1 + EPCs were isolated as described (6) . Briefly, BM cells were depleted of erythrocytes by hypotonic lyses. Lin -cells were separated by negative selection using the Mouse Hematopoietic Progenitor Cell Enrichment Kit (StemCell). The cells were labeled with biotinylated Sca-1 antibody and isolated with streptavidin magnetic particles. EPCs were resuspended in endothelial growth medium (EGM-2) supplemented with EGF, hydrocortisone, VEGF, bFGF, heparin, IGF, gentamicin, and 5% FBS (Lonza), and cultured on fibronectin (10 μg/mL)-coated plates.
Matrigel Vasculogenesis Model. Freshly isolated EPCs were resuspended on ice in phenol red-free Matrigel solution and implanted into female C57BL/6J mice by abdominal s.c. injection (200 μL). Matrigel plugs were retrieved on day 7 after implantation, photographed with a Leica M165FC stereoscopic microscope, and each divided into four portions for hematoxylin and eosin staining, fluorescent immunostaining, recovering the cells and preparing cell-free homogenates, and Western blotting.
Statistical Analysis. The data were subjected to variance analysis (ANOVA), followed by two-tailed, unpaired Student t test. Differences with P values less than 0.05 were considered to be statistically significant. Other reagents and experimental procedures are included in SI Materials and Methods.
